广州宏畅生物科技有限公司坐落于美丽的广州国际生物岛，是一家以人体组织器官的再生修复为目标，致力于生物人工医疗器械和组织工程产品的研发、生产和销售的高新技术企业。实缴注册资金2000万元。公司已建成符合国家规范的GMP标准厂房并取得国家医疗器械生产许可证。

        公司敏锐抓住“再生医学时代”的契机，瞄准市场对组织器官修复、再生与替代的迫切需求，以造福人类为宗旨，潜心产品研发，以产、学、研为基本模式，积极推动自主创新。多年来集研发与创新、转化与生产、产业与流通为一体，注重人才培养与团队打造，以市场为导向、产品为出口，不断攻克技术难关，现已研发出具有自主知识产权、处于国际领先水平的小口径生物人工血管，有望填补国内外在小口径血管修复替代治疗上的空白。此外公司将再生修复的核心技术运用于生物人工带瓣管道、生物人工角膜、新型生物美容产品、干细胞与组织工程联合治疗等的研发与生产。

       以资本为纽带，以人才为动力，以科技为引领，公司正昂首走在生物再生医疗产品制造的星光大道上。

Guangzhou Hongchang Biotechnology Co., Ltd. is located on the beautiful Guangzhou International Bio Island. It is a high-tech enterprise dedicated to the research, development, production, and sales of biologically engineered medical devices and tissue engineering products with a focus on regenerative repair of human tissue and organs. The company has a registered capital of 20 million Yuan. It has established GMP-standard workshops in compliance with national regulations and obtained a national medical device production license.

Seizing the opportunity of the 'regenerative medicine era,' the company targets the urgent market demand for tissue and organ repair, regeneration, and replacement. With the aim of benefiting humanity, it diligently engages in product research and development, adopting a model of integrating production, academia, and research, and actively promotes independent innovation. Over the years, the company has integrated research and development, innovation, transformation, production, industry, and distribution, focusing on talent cultivation and team building. Guided by the market and driven by product exports, it continuously overcomes technological challenges.

The company has successfully developed small-caliber artificial blood vessels with independent intellectual property rights and at an internationally advanced level, which are expected to fill the gap in the field of small-caliber blood vessel repair and replacement therapy both domestically and internationally. Additionally, the core technology of regenerative repair is applied to the research and production of biologically engineered valved conduits, biologically engineered corneas, new types of biologically engineered cosmetic products, and combined therapies involving stem cells and tissue engineering.

With capital as a link, talent as a driving force, and technology as a guide, the company is confidently advancing on the starlit road of manufacturing bio-regenerative medical products.